Advancements in antibody engineering technologies have greatly enhanced the generation of recombinant antibodies in various formats as therapeutic agents. There are already more than 100 antibody-based drugs approved by the FDA, and numerous antibodies are currently in their late-stage clinical studies. Compared to monoclonal antibodies produced using traditional hybridoma techniques, recombinant antibodies offer advantages, such […]
Menu ≡ ╳ 
